Works by Reeves, Brandi N.


Results: 8
    1
    2

    Phase I study of opaganib, an oral sphingosine kinase 2-specific inhibitor, in relapsed and/or refractory multiple myeloma.

    Published in:
    Annals of Hematology, 2023, v. 102, n. 2, p. 369, doi. 10.1007/s00277-022-05056-7
    By:
    • Kang, Yubin;
    • Sundaramoorthy, Pasupathi;
    • Gasparetto, Cristina;
    • Feinberg, Daniel;
    • Fan, Shengjun;
    • Long, Gwynn;
    • Sellars, Emily;
    • Garrett, Anderson;
    • Tuchman, Sascha A.;
    • Reeves, Brandi N.;
    • Li, Zhiguo;
    • Liu, Bei;
    • Ogretmen, Besim;
    • Maines, Lynn;
    • Ben-Yair, Vered Katz;
    • Smith, Charles;
    • Plasse, Terry
    Publication type:
    Article
    3
    4
    5
    6
    7
    8

    A multicenter study to assess efficacy, safety, and tolerability of ropeginterferon alfa-2b-njft in patients with essential thrombocythemia in the US and Canada: EXCEED-ET trial.

    Published in:
    Frontiers in Medicine, 2025, p. 1, doi. 10.3389/fmed.2025.1548590
    By:
    • Masarova, Lucia;
    • Reeves, Brandi N.;
    • El Chaer, Firas;
    • Foltz, Lynda;
    • Tashi, Tsewang;
    • Abu-Zeinah, Ghaith;
    • Lucas, Jennifer;
    • Halpern, Anna B.;
    • Maze, Dawn;
    • Qin, Albert;
    • Safah, Hana;
    • Lan, Fengshuo;
    • O'Connell, Casey L.;
    • Goel, Swati;
    • Rein, Lindsay;
    • Fang, Bruno;
    • How, Joan;
    • Babu, Sunil;
    • Li, Zhuoyan;
    • Cerquozzi, Sonia
    Publication type:
    Article